Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nls Pharmaceutics Ltd WT
(NQ:
NLSPW
)
0.0409
+0.0159 (+63.60%)
Streaming Delayed Price
Updated: 10:28 AM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nls Pharmaceutics Ltd WT
< Previous
1
2
3
Next >
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
January 30, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
January 25, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
January 23, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
January 12, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up to $30 Million
December 07, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development
September 08, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement
January 12, 2023
Via
ACCESSWIRE
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
January 11, 2023
Via
ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
December 22, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
December 14, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
December 07, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder
December 01, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe
November 23, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice
November 14, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy
November 07, 2022
Via
ACCESSWIRE
U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH)
November 02, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
October 05, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes
October 03, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience(R) (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
September 27, 2022
Via
ACCESSWIRE
NLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience(R) Top-Line Phase 2a Narcolepsy Results
September 19, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
July 28, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / July 28, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
July 28, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
July 21, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
July 21, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / July 21, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification
June 10, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
June 06, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Bankruptcy
Initial Public Offering
Exposures
Financial
Legal
Securities Market
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy
June 02, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 2, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy
May 04, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
April 26, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference
April 22, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.